| Agilent to Participate in Jefferies Global Healthcare Conference |
SANTA CLARA, Calif--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at the Jefferies Global Healthcare Conference at 10:30 a.m. Eastern on Wednesday, June 4, 2025, in New York City. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in anal. |
businesswire.com |
2025-05-15 20:14:00 |
Czytaj oryginał (ang.) |
| Scale Has Its Advantages: 3 A-Rated REIT Monopolies |
Scale is a critical competitive advantage for companies, enabling them to expand, attract capital, and achieve strong market positions, as seen with Realty Income, Prologis, and Public Storage. Realty Income leverages its scale and diversification to maintain high occupancy rates and strong financial performance, boasting a fortress balance sheet and impressive dividend growth. Prologis excels with its vast warehouse portfolio, robust development pipeline, and strategic expansion into data centers, supported by a strong balance sheet and high earnings growth. |
seekingalpha.com |
2025-05-10 11:00:00 |
Czytaj oryginał (ang.) |
| Will Agilent (A) Beat Estimates Again in Its Next Earnings Report? |
Agilent (A) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report. |
zacks.com |
2025-05-02 17:10:36 |
Czytaj oryginał (ang.) |
| The Preferred Stock IPO Market Is Frozen |
This month's preferred stock IPO market is frozen, dominated by “Par Cross” and “Insider Buying” alerts, reflecting investor uncertainty due to trade tensions. The trade war and tariffs have created significant market volatility, causing companies to withdraw earnings guidance and defer investment decisions. Preferred stocks and baby bonds offer fixed payments, making them attractive during uncertain times, as they provide a “known return” amidst market unpredictability. |
seekingalpha.com |
2025-05-01 01:50:55 |
Czytaj oryginał (ang.) |
| Why Investors Need to Take Advantage of These 2 Medical Stocks Now |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-04-29 13:56:14 |
Czytaj oryginał (ang.) |
| City Office REIT (RED PFD SER A): A High Yield, Deep Value Opportunity Worth Latching Onto |
City Office REIT's Series A Preferred Shares offer a tempting yield despite recent accounting losses and systemic pressures, suggesting a potential buying opportunity. The shares are cumulative, redeemable, and fixed, ensuring eventual dividend payments, though call risk and financial restructuring are potential concerns. The REIT's fundamentals, including an 85.8% occupancy rate and sector diversification, support sustainability, with positive economic profitability and AFFO figures. |
seekingalpha.com |
2025-04-24 13:52:15 |
Czytaj oryginał (ang.) |
| Smackover Lithium's South West Arkansas Project Receives Unanimous Vote of Approval to Establish the Phase I Brine Production Unit from the Arkansas Oil and Gas Commission |
LEWISVILLE, Ark., April 24, 2025 (GLOBE NEWSWIRE) -- Smackover Lithium, a Joint Venture (“JV”) between Standard Lithium Ltd. |
globenewswire.com |
2025-04-24 12:30:00 |
Czytaj oryginał (ang.) |
| Agilent Showcases Solutions and Partnerships Transforming Cancer Research and Therapeutics at AACR 2025 |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today its participation at the American Association for Cancer Research (AACR) Annual Meeting on April 25-30, 2025 in Chicago, Illinois. Innovative Agilent products and partnerships playing a crucial role in transforming cancer research, diagnostics, and therapeutics will be featured, including: Agilent Avida DNA Cancer Panels – Based on cutting-edge next-generation sequencing (NGS) target enrichment solutions t. |
businesswire.com |
2025-04-24 12:00:00 |
Czytaj oryginał (ang.) |
| Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced. |
businesswire.com |
2025-04-17 12:00:00 |
Czytaj oryginał (ang.) |
| Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names |
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. |
zacks.com |
2025-04-11 13:55:39 |
Czytaj oryginał (ang.) |
| Agilent placed on 'positive catalyst watch' at Citi |
Citi analyst Patrick Donnelly added a "90-day positive catalyst watch" on shares of Agilent while keeping a Buy rating on the name with a $165 price target. At a time when investor sentiment on tools is negative, the higher end of the Agilent's fiscal Q2 growth guidance is achievable and its fiscal year numbers "are safe," the analyst tells investors in a research note. Citi is encouraged by Agilent's order book. |
https://thefly.com |
2025-04-07 10:14:42 |
Czytaj oryginał (ang.) |
| Fear Creates Fortunes: Grab These 7 Blue-Chip Bargains Today |
Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data shows inflation is falling, contradicting consumer fears and demonstrating that stagflation panic may be premature. |
seekingalpha.com |
2025-04-03 11:00:00 |
Czytaj oryginał (ang.) |
| Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a. |
businesswire.com |
2025-03-24 10:00:00 |
Czytaj oryginał (ang.) |
| CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025 |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will. |
businesswire.com |
2025-03-20 15:37:00 |
Czytaj oryginał (ang.) |
| Agilent to Showcase Next-Generation Digital Pathology Solutions at USCAP 2025 |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzing tissue samples, often for dia. |
businesswire.com |
2025-03-20 10:00:00 |
Czytaj oryginał (ang.) |
| Agilent Research Catalyst Award Presented to Columbia University for Professor Pawel Muranski |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Med. |
businesswire.com |
2025-03-19 10:00:00 |
Czytaj oryginał (ang.) |
| Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Companion Diagnostic Test for Non-small Cell Lung Cancer and Melanoma Indications |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusiv. |
businesswire.com |
2025-03-10 10:19:00 |
Czytaj oryginał (ang.) |
| Agilent Technologies, Inc. (A) TD Cowen 45th Annual Healthcare Conference (Transcript) |
Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Alright, good. I guess we'll start in a minute or two early here, great day two of the TD Cowen Global Healthcare Conference. |
seekingalpha.com |
2025-03-04 17:55:36 |
Czytaj oryginał (ang.) |
| Unlocking Agilent (A) International Revenues: Trends, Surprises, and Prospects |
Explore how Agilent's (A) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects. |
zacks.com |
2025-03-03 12:21:01 |
Czytaj oryginał (ang.) |
| Agilent to Participate in TD Cowen Health Care Conference |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell — along with CFO Bob McMahon — will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference at 9:50-10:20 a.m. Eastern on Tuesday, March 4, 2025, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a globa. |
businesswire.com |
2025-02-27 23:29:00 |
Czytaj oryginał (ang.) |
| Agilent Technologies, Inc. (A) Q1 2025 Earnings Call Transcript |
Agilent Technologies, Inc. (NYSE:A ) Q1 2025 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Parmeet Ahuja - Vice President of Investor Relations Padraig McDonnell - President and Chief Executive Officer Robert W. McMahon - Senior Vice President and Chief Financial Officer Simon May - President of Life Sciences and Diagnostics Markets Group Angelica Riemann - President of Agilent CrossLab Group Mike Zhang - President of Applied Markets Group Conference Call Participants Rachel Vatnsdal - J.P. |
seekingalpha.com |
2025-02-26 23:28:56 |
Czytaj oryginał (ang.) |
| Agilent (A) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Agilent (A) give a sense of how its business performed in the quarter ended January 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-26 21:00:31 |
Czytaj oryginał (ang.) |
| Agilent Technologies (A) Q1 Earnings and Revenues Beat Estimates |
Agilent Technologies (A) came out with quarterly earnings of $1.31 per share, beating the Zacks Consensus Estimate of $1.27 per share. This compares to earnings of $1.29 per share a year ago. |
zacks.com |
2025-02-26 20:16:11 |
Czytaj oryginał (ang.) |
| Agilent lowers annual revenue forecast on soft demand for medical equipment |
Medical equipment maker Agilent lowered its annual revenue forecast on Wednesday, as it expects soft demand for its medical tools and equipment from smaller biotech companies. |
reuters.com |
2025-02-26 18:46:12 |
Czytaj oryginał (ang.) |
| Agilent Reports First-Quarter Fiscal Year 2025 Financial Results |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.68 billion for the first quarter ended Jan. 31, 2025, representing growth of 1.4% reported and up 1.2% core(1) compared to the first quarter of 2024. First-quarter GAAP net income was $318 million, or $1.11 per share. This compares with $348 million, or $1.18 per share, in the first quarter of fiscal year 2024. Non-GAAP(2) net income was $377 million, or $1.31 per share during the quarter, com. |
businesswire.com |
2025-02-26 18:04:00 |
Czytaj oryginał (ang.) |
| Agilent to Report Q1 Earnings: What's in the Cards for the Stock? |
A's fiscal first-quarter performance is likely to have been influenced by higher expenses, increased CapEx and the Lunar New Year timing shift. |
zacks.com |
2025-02-24 16:30:27 |
Czytaj oryginał (ang.) |
| What Analyst Projections for Key Metrics Reveal About Agilent (A) Q1 Earnings |
Besides Wall Street's top -and-bottom-line estimates for Agilent (A), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended January 2025. |
zacks.com |
2025-02-21 12:21:26 |
Czytaj oryginał (ang.) |
| Agilent to Announce First-Quarter Fiscal Year 2025 Financial Results on Feb. 26 |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2025 after the stock market closes on Wednesday, Feb. 26. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PST. To join the listen-only conference call webcast, click the link on the Events section of Agilent's investor relations website. A recording of the call also will be available on the website for 90 days. Abo. |
businesswire.com |
2025-01-24 19:59:00 |
Czytaj oryginał (ang.) |
| Agilent Automated Workflows at SLAS2025: Connecting with Confidence |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will feature new automated laboratory workflow solutions at the SLAS2025 International Conference & Exhibition being held January 25-29, at the San Diego Convention Center in California. Agilent is a leader in advancing automation solutions to help customers optimize lab performance, efficiency, and reproducibility across their entire pipeline, from research and drug discovery to development an. |
businesswire.com |
2025-01-24 10:00:00 |
Czytaj oryginał (ang.) |
| Agilent Rises 11% in a Year: Should You Buy, Sell or Hold the Stock? |
A faces challenges with slowing end-market demand and regulatory hurdles in China, raising growth concerns. |
zacks.com |
2025-01-16 16:01:09 |
Czytaj oryginał (ang.) |
| Agilent Technologies, Inc. (A) J.P. Morgan 43rd Annual Healthcare Conference (Transcript) |
Agilent Technologies, Inc. (NYSE:A ) J.P. Morgan 43rd Annual Healthcare Conference January 14, 2025 12:45 PM ET Company Participants Padraig McDonnell - President and CEO Robert McMahon - Senior VP and CFO Conference Call Participants Rachel Vatnsdal - JPMorgan Rachel Vatnsdal Good morning, everyone. |
seekingalpha.com |
2025-01-15 11:17:05 |
Czytaj oryginał (ang.) |
| Reaves Utility Income Fund Section 19(A) Notice |
DENVER, CO / ACCESSWIRE / December 30, 2024 / On December 30, 2024, the Reaves Utility Income Fund (NYSE American:UTG) (the "Fund"), a closed-end sector fund, paid a monthly distribution on its common stock of $0.19 per share to shareholders of record at the close of business on December 16, 2024. The following table sets forth the estimated amount of the sources of distribution for purposes of Section 19 of the Investment Company Act of 1940, as amended, and the related rules adopted thereunder. |
accesswire.com |
2024-12-30 08:59:00 |
Czytaj oryginał (ang.) |
| Agilent (A) Up 1.3% Since Last Earnings Report: Can It Continue? |
Agilent (A) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-25 14:31:11 |
Czytaj oryginał (ang.) |
| Is the Options Market Predicting a Spike in Agilent (A) Stock? |
Investors need to pay close attention to Agilent (A) stock based on the movements in the options market lately. |
zacks.com |
2024-12-23 11:36:08 |
Czytaj oryginał (ang.) |
| Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical lab. |
businesswire.com |
2024-12-19 15:45:00 |
Czytaj oryginał (ang.) |
| Agilent investor day calls for margin expansion, says Goldman Sachs |
Goldman Sachs keeps a Buy rating and $150 price target on Agilent after the company's investor day presentation. The firm's main takeaways from the event are the forecast for operating margin expansion, with the management calling for 50-100+bps of annual expansion embedded in long-term guidance, a long-term revenue growth target of 5%-7% annually, and the focus on China despite the near-term challenges as the region continues to normalize, the analyst tells investors in a research note. |
https://thefly.com |
2024-12-17 19:45:53 |
Czytaj oryginał (ang.) |
| Agilent CEO Padraig McDonnell sees 'long runway' in advancing therapeutics |
Padraig McDonnell, Agilent CEO, joins 'Closing Bell Overtime' to talk investors day, its healthcare segment, and more. |
youtube.com |
2024-12-17 19:34:30 |
Czytaj oryginał (ang.) |
| Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autosta. |
businesswire.com |
2024-12-10 13:09:00 |
Czytaj oryginał (ang.) |
| Agilent Gains 5% in a Month: Should You Buy, Sell or Hold the Stock? |
A's shares ride on the bright performance of the Agilent CrossLab Group segment and strategic acquisitions. |
zacks.com |
2024-12-09 15:25:25 |
Czytaj oryginał (ang.) |
| International Markets and Agilent (A): A Deep Dive for Investors |
Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock. |
zacks.com |
2024-12-02 16:30:34 |
Czytaj oryginał (ang.) |
| Agilent Q4 Earnings Surpass Estimates, Revenues Increase Y/Y |
A's fourth-quarter 2024 results benefit from strong demand in the ACG segment. However, declining sales in the Americas and China markets raise concerns. |
zacks.com |
2024-11-26 17:06:18 |
Czytaj oryginał (ang.) |
| Agilent Q4: Expecting Market Recovery In 2025 |
I reiterate a “Buy” rating on Agilent Technologies, Inc. with a one-year target price of $150 per share, driven by strategic growth and market recovery. Agilent's acquisition of BIOVECTRA will enhance its CDMO business, focusing on oligonucleotides and CRISPR therapeutics, and expand service offerings in peptide synthesis. Agilent's FY25 guidance includes 2.5%-3.5% core revenue growth and 5.8% adjusted EPS growth, aligned with market expectations and supported by segment-specific growth strategies. |
seekingalpha.com |
2024-11-26 13:37:39 |
Czytaj oryginał (ang.) |
| Agilent Technologies, Inc. (A) Q4 2024 Earnings Call Transcript |
Agilent Technologies, Inc. (NYSE:A ) Q4 2024 Results Conference Call November 25, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Vice President, Investor Relations Padraig McDonnell - President and CEO Bob McMahon - Senior Vice President and CFO Simon May - President, Life Sciences and Diagnostic Markets Group Phil Binns - President, Life Sciences & Applied Markets Group Angelica Riemann - President, Agilent CrossLab Group Mike Zhang - President, Applied Markets Group Conference Call Participants Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Vijay Kumar - Evercore ISI Jack Meehan - Nephron Research Dan Leonard - UBS Puneet Souda - Leerink Partners Tycho Peterson - Jefferies Brandon Couillard - Wells Fargo Doug Schenkel - Wolfe Research Michael Ryskin - Bank of America Dan Brennan - TD Cowen Operator Good afternoon. My name is Rob, and I will be your conference operator today. |
seekingalpha.com |
2024-11-25 23:03:01 |
Czytaj oryginał (ang.) |
| Agilent (A) Reports Q4 Earnings: What Key Metrics Have to Say |
The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended October 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-25 21:01:12 |
Czytaj oryginał (ang.) |
| Dow and Small-Caps Close at New All-Time Highs |
The Dow closed at a fresh new high at 44,736, +440 points on the day, and the Russell 2000 notched its first all-time closing high since 2021. |
zacks.com |
2024-11-25 20:55:32 |
Czytaj oryginał (ang.) |
| Agilent Technologies (A) Beats Q4 Earnings and Revenue Estimates |
Agilent Technologies (A) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.38 per share a year ago. |
zacks.com |
2024-11-25 20:16:09 |
Czytaj oryginał (ang.) |
| Medical equipment maker Agilent's downbeat annual forecast clouds fourth-quarter beat |
Agilent forecast its annual profit below analysts' estimates on Monday, as a recovery is ongoing in the market for medical tools and equipment used in clinical studies, sending its shares down more than 2% after the bell. |
reuters.com |
2024-11-25 19:08:53 |
Czytaj oryginał (ang.) |
| Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023. Fourth-quarter GAAP net income was $351 million, or $1.22 per share. This compares with $475 million, or $1.62 per share, in the fourth quarter of fiscal year 2023. Non-GAAP(2) net income was $418 million, or $1.46 per share during the qua. |
businesswire.com |
2024-11-25 18:05:00 |
Czytaj oryginał (ang.) |
| Agilent Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts |
Agilent Technologies, Inc. A will release earnings results for the fourth quarter, after the closing bell on Monday, Nov. 25. |
benzinga.com |
2024-11-25 14:36:06 |
Czytaj oryginał (ang.) |
| Agilent Announces New Organizational Structure to Support its Market-Focused Strategy |
SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a new organizational structure to accelerate the company's operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately. “This is an important step in our transformation to become a nimbler company that puts our customers and our markets first,” said Agilent President and CEO Pad. |
businesswire.com |
2024-11-25 11:01:00 |
Czytaj oryginał (ang.) |
| Agilent to Report Q4 Earnings: What's in the Cards for the Stock? |
A's fourth-quarter performance is expected to have benefited from the growing ACG segment. However, falling end-market and regional sales raise concerns. |
zacks.com |
2024-11-22 15:35:18 |
Czytaj oryginał (ang.) |